Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the benefit of the HAbility Home device, a digital therapeutic using a wireless virtual reality headset, for supervised self-rehabilitation at home in adults who have had their first stroke. This prospective, multicenter, randomized, controlled, crossover study aims to compare the impact of this device on patients autonomy with the use of traditional paper-based exercise guides during post-stroke rehabilitation. Participants will be randomized into two groups one using the HAbility Home device for six weeks followed by a one-week washout and then six weeks using the paper-based guide, and the other group following the reverse sequence. The device includes software designed for neurological rehabilitation, and exercises are performed at home. The washout period involves no self-rehabilitation exercises. Participants will undergo screening and baseline assessments before starting. Throughout the study, researchers will evaluate autonomy, walking speed, coordination, quality of life, satisfaction with rehabilitation exercises, cognitive abilities, fear of falling, compliance, device acceptability, mental load, and motion sickness. Assessments occur at screening, baseline, six weeks, seven weeks after washout, and thirteen weeks. The study includes safety and compliance monitoring and lasts approximately 13 weeks per participant.
Actively Recruiting
Cystic fibrosis is a genetic disease caused by mutations in the gene for the CFTR protein, leading to respiratory and digestive problems that affect health outcomes. Digestive issues can cause malnutrition with reduced muscle mass, which is linked to poorer lung function. Recently, undernutrition has been redefined to include loss of muscle mass or function. The therapy Elexacaftor-Tezacaftor-Ivacaftor, approved in 2021, aims to improve CFTR protein function and has shown early benefits in lung function and weight gain, but also new nutritional challenges like overweight and metabolic problems. This study explores how diet and exercise can help these patients. The study compares two groups of adults with cystic fibrosis treated with Elexacaftor-Tezacaftor-Ivacaftor. One group participates in the DIAPASOM program, which includes a year-long remote adapted physical activity program led by a specialist instructor, with phases of supervised and independent sessions, combined with personalized dietetic care involving consultations every three months and phone follow-ups. The other group receives usual care for nutrition and physical activity. Participants will be followed for 12 months to assess changes in lean body mass as a percentage of total body mass. Researchers will also measure fat mass, weight, BMI, muscle strength and endurance, flexibility, lung function, physical activity levels, sedentary time, and quality of life. The programs feedback questionnaire will be collected at 12 months. This thorough evaluation aims to understand how coordinated diet and adapted physical activity affect muscle mass and overall health in cystic fibrosis patients.
Actively Recruiting
Researchers are investigating the effects of the new combination treatment elexacaftortezacaftorivacaftor in children with cystic fibrosis, a disease that primarily affects the lungs and digestive system through chronic inflammation. This trial aims to understand how this treatment influences the lung and gut microbiota and inflammation. The study builds on previous research with a different treatment combination and uses an existing cohort and sample collection system to gather biological data over one year. Participants will receive elexacaftortezacaftorivacaftor as part of their routine care. Samples of sputum, stool, and blood will be collected at treatment start, six months, and one year later to analyze changes in lung and digestive bacterial and fungal communities. This approach allows researchers to study the interplay between the lung and gut microbiota during treatment. During the study, participants will provide biological samples at three time points for detailed microbiota and inflammation analysis. Researchers will measure the composition of digestive and pulmonary bacterial and fungal microbiota at baseline and after one year of treatment. The study lasts one year from treatment initiation, with ongoing monitoring to assess the treatments impact on these important health markers.
Actively Recruiting
Bronchiectasis is a chronic lung condition where parts of the airways are permanently widened, causing mucus buildup, infections, and ongoing inflammation. This study evaluates the long-term use of the SIMEOX medical device at home, combined with remote physiotherapy, to improve quality of life and reduce lung flare-ups in adults with non-cystic fibrosis bronchiectasis. The research compares this approach to enhanced standard care including remote physiotherapy alone. Participants will be randomly assigned to either standard care with remote physiotherapy or to use the SIMEOX device daily at home alongside remote physiotherapy. Remote physiotherapy sessions occur once a month for the first three months and then every three months. The study spans an average of 24 months to assess the effects of adding the SIMEOX device to usual care. During the study, participants will complete quality of life questionnaires and undergo lung function tests at 6, 12, and 24 months. The main outcomes measured include the yearly rate of lung exacerbations and changes in quality of life scores. Researchers will also track hospitalizations, treatment compliance, adverse events, and lung function changes. The long follow-up aims to evaluate the sustained impact of the device and physiotherapy on participants respiratory health.
Actively Recruiting
Researchers are investigating the use of Porphyromonas as a biomarker to predict the risk of initial colonization by Pseudomonas aeruginosa in children aged 0 to 18 years who have cystic fibrosis. This study is descriptive and monocentric, aiming to identify and validate biomarkers that may predict clinical evolution in these patients. The study consists of three phases pre-inclusion at the first visit to the Cystic Fibrosis Reference Center CRCM, inclusion between the second visit around 2 months old and six months of age, and follow-up until the child reaches 36 months old. During the study, clinical and paraclinical data along with biological samples such as bronchial secretions, blood, stools, superficial skin, dental plaque, and urine will be collected. Dermatological and dental follow-ups are scheduled annually at a regional hospital. Participants will attend visits based on the usual care schedule for cystic fibrosis infants. Respiratory tests and sample collections will be performed during these visits at the CRCM. The primary outcome measured is the presence of Pseudomonas aeruginosa in bronchial secretions over the three-year period. The study includes monitoring through clinical exams and biological testing to track the development and colonization status of the children.
Actively Recruiting
This research investigates how adults with cystic fibrosis feel about switching from their current treatment with elexacaftortezacaftorivacaftor ETI to a newer therapy called vanzacaftortezacaftordeutivacaftor VTD. It focuses on patients willingness to change treatments and examines factors like treatment satisfaction, knowledge about VTD, quality of life, and concerns related to side effects and access. The study includes both questionnaires and interviews to understand patients views and decision-making. Participants include adults treated with ETI for at least three months or those who stopped ETI for medical reasons. The study does not require participants to change treatments but observes their preferences and related characteristics. Data are collected through specific questionnaires during routine visits or hospital stays, and some participants take part in detailed interviews lasting 30 to 45 minutes. The study collects information on quality of life, treatment adherence, and adverse effects from medical records. Throughout the study, participants complete questionnaires at one time point, and a smaller group participates in interviews to explore psychological and logistical challenges. Researchers analyze responses to understand intentions to switch treatment and identify support needs. The study is observational, with data collection integrated into routine care, and is expected to include about 343 participants for the questionnaires and 8 to 12 for interviews. Participation lasts for the duration of data collection around a routine visit or hospital stay.
Actively Recruiting
Cystic fibrosis CF causes changes in how the body processes antibiotics, affecting absorption, distribution, metabolism, and elimination. These changes historically led to higher antibiotic doses to reach effective concentrations and improve lung health. The introduction of the triple combination drug elexacaftortezacaftorivacaftor ETI has greatly improved lung function, nutrition, inflammation, and quality of life in CF patients, while also altering respiratory infections and reducing lung flare-ups. This observational study tracks intravenous antibiotic levels in adolescents and adults with CF who are receiving ETI during lung exacerbations needing antibiotic treatment. Routine antibiotic therapy and drug monitoring follow standard care practices, with no additional interventions assigned. The study compares antibiotic concentrations to current recommended targets to understand how ETI may affect antibiotic dosing needs. Participants will be monitored through blood tests to measure antibiotic levels on day 3 of therapy, along with clinical assessments of weight, temperature, appetite, fatigue, breathing difficulty, sputum amount and quality, kidney function, and inflammation at various points during treatment. Treatment adherence and any side effects will also be tracked over about 14 days. The study aims to help optimize antibiotic dosing in CF patients treated with ETI while minimizing side effects.